AstraZeneca, GB0009895292

AstraZeneca stock: Klygefa wins US and EU approvals

Published on 11/16/2026 at 17:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock is in focus after Klygefa won approvals in the US and EU. The rare-disease drug adds a new treatment option for eligible adults.

Key developments for investors

  • Klygefa received US and EU approvals for adults with AChR-positive generalised myasthenia gravis.
  • The PREVAIL Phase III trial showed a statistically significant improvement in daily-living activities.
  • AstraZeneca stock traded at 168.10 euros on Lang & Schwarz on Monday afternoon.
AstraZeneca, GB0009895292, Illustration mit AI erstellt.

AstraZeneca announced on Monday, November 16, 2026, that Klygefa (gefurulimab) had been approved in the United States and the European Union for adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis. The company described the medicine as the first approved dual-binding nanobody C5 inhibitor in both markets, according to its US release and EU release.

Approvals expand rare-disease reach

The US Food and Drug Administration approval covers adults with generalised myasthenia gravis who are anti-acetylcholine receptor antibody positive. The European Commission approved Klygefa as an add-on to standard therapy for the same patient group.

The approvals were based on the PREVAIL Phase III trial. AstraZeneca said the study met its primary endpoint, with a treatment difference of -1.6 in the Myasthenia Gravis Activities of Daily Living score at week 26 compared with placebo. Clinical improvement was observed from week one and continued through week 26.

Once-weekly administration

Klygefa is designed for once-weekly subcutaneous self-administration through an autoinjector. AstraZeneca said the treatment was generally well tolerated in the trial, while the US release listed injection-site reactions, back pain and vomiting among the most common treatment-emergent adverse events.

AstraZeneca stock traded at 168.10 euros on Lang & Schwarz at 17:40 CET on Monday, November 16, 2026.

AstraZeneca at a glance

  • Company: AstraZeneca PLC
  • ISIN: GB0009895292
  • Quote: 168.10 euros on Lang & Schwarz at 17:40 CET, Monday, November 16, 2026
  • Business: Biopharmaceuticals, oncology and rare diseases

The UK market environment can be followed in Current market reports.

More news and analyses on AstraZeneca stock.

Disclaimer...
en | GB0009895292 | ASTRAZENECA | boerse | 70521864 | bgmi